ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1210

Non-Responders to Total Joint Replacement Therapy in Osteoarthritis Patients and Novel Metabolic Markers

Guangju Zhai1, Ming Liu2, Quan Li1, Andrew Furey1, Weidong Zhang3, Sergei Likhodi1, Edward Randell1 and Proton Rahman4, 1Memorial University of Newfoundland, St. John's, NF, Canada, 2Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 3Jilin University, Changchun, China, 4Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers, metabolomics, osteoarthritis and total joint replacement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, and is the major source of joint pain and disability. The aim of the study was to estimate the percentage of non-responders to total joint replacement therapy (TJR) in OA (hip and knee) patients and identify factors and biomarkers that associated with it.

Methods: TJR patients due to OA were recruited at the surgery and followed up for 4 years on average. The WOMAC pain and function subscales at pre- and post-surgery were used to assess the improvement of joint pain and function. Based on the minimal clinically important difference (MCID), participants were classified as non-responders if the change score of less than 7 points (of 20 points total) for WOMAC pain subscale from pre-surgery to post-surgery. For physical function, participants were non-responders if the change score was less than 22 points (of a total of 68) from pre-surgery to post-surgery. Metabolic profiling (186 targeted metabolites) was performed on plasma samples collected at baseline. Demographic and medical information was collected systematically using standardized questionnaires.

Results: A total of 242 TJR patients were included, 20% were hip replacements and 80% were knee replacements. 42% of them were males and 58% were females. Mean age was 65.6 ±7.4 years old. 16.5% of the study participants were classified as non-responders to TJR, as they failed to reach MCID for pain. A similar percentage for non-responders was noted for physical function. There was no difference between knee and hip replacements. About 63% of the non-responders as defined by pain score were also non-responders in physical function. No association was noted between the non-responders in pain and physical function and clinical epidemiological factors including age, sex, BMI, and comorbidities (cardiovascular disease, metabolic related disease, and cancers). However, four amino acids – histidine, sarcosine, phenylalaine, and serine levels were significantly associated with non-responders in physical function (all adjusted p values (FDR)<0.05). Phenylalanine level was also associated with non-responders in pain although the significance didn’t pass the multiple testing adjustments by FDR (unadjusted p=0.02).

Conclusion: Our data indicated that over 16% of OA patients did not reach MCID from TJR in either pain or physical function and non-responders to TJR were associated with higher levels of several amino acids. While further confirmation is needed, our findings have great potential in the clinical decision-making process when contemplating TJR for knee or hip OA.


Disclosure: G. Zhai, None; M. Liu, None; Q. Li, None; A. Furey, None; W. Zhang, None; S. Likhodi, None; E. Randell, None; P. Rahman, Janssen Pharmaceutica Product, L.P., 8,Amgen, AbbVie, BMS, Celgene, Pfizer, Janssen, Wyeth, EliLiiy, Novartis, 8,Amgen, AbbVie, BMS, Celgene, Pfizer, Janssen, Wyeth, EliLiiy, Novartis, 5.

To cite this abstract in AMA style:

Zhai G, Liu M, Li Q, Furey A, Zhang W, Likhodi S, Randell E, Rahman P. Non-Responders to Total Joint Replacement Therapy in Osteoarthritis Patients and Novel Metabolic Markers [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/non-responders-to-total-joint-replacement-therapy-in-osteoarthritis-patients-and-novel-metabolic-markers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-responders-to-total-joint-replacement-therapy-in-osteoarthritis-patients-and-novel-metabolic-markers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology